Mobilisation of peripheral blood stem cells with IVE and G-CSF improves CD34+ cell yields and engraftment in patients with non-Hodgkin's lymphomas and Hodgkin's disease

Bone Marrow Transplantation

Volumn 24, Issue 7, 1999, Pages 715-722

  McQuaker, I G ^a   Haynes, A P ^a,b   Stainer, C ^a   Byrne, J L ^a,b   Russell, N H ^a,b,c  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Autologous transplantation; CD34+ cells; IVE; Lymphoma; PBSC

Indexed keywords

CD34 ANTIGEN; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; PREDNISOLONE;

ADULT; ARTICLE; BLOOD CELL COUNT; CLINICAL TRIAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; HUMAN CELL; LEUKAPHERESIS; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE COUNT;

EID: 0032836985     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701985     Document Type: Article

References (32)

1. Freedman AS, Takvorian T, Anderson KC et al. Autologous bone marrow transplantation in B cell non-Hodgkin's lymphoma - very low treatment-related mortality in 100 patients in sensitive relapse. J Clin Oncol 1990; 8: 784-791.
2. Gribben JG, Goldstone AH, Linch DC et al. Effectiveness of high-dose combination chemotherapy and autologous bone marrow transplantation for patients with non-Hodgkins lymphomas who are still responsive to conventional-dose therapy. J Clin Oncol 1989; 7: 1621-1629.
3. Philip T, Armitage JO, Spitzer G et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. New Engl J Med 1987; 316: 1493-1498.
4. Freedman AS, Ritz J, Neuberg D et al. Autologous bone marrow transplantation in 69 patients with a history of low-grade non-Hodgkin's lymphoma. Blood 1991; 77: 2524-2529.
5. Schouten HC, Bierman PJ, Vaughan WP et al. Autologous bone marrow transplantation in follicular non-Hodgkin's lymphoma before and after histological transformation. Blood 1989; 74: 2579-2584.
6. Rohatiner AZS, Johnson PWM, Price CGA et al. Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol 1994; 12: 1177-1184.
7. Colombat P, Donadio D, Fouillard L et al. Value of autologous bone marrow transplantation in follicular lymphoma: a France Autogreffe retrospective study of 42 patients. Bone Marrow Transplant 1994; 13: 157-162.
8. Morel P, Laporte JP, Noel MP et al. Autologous bone marrow transplantation as a consolidation therapy may prolong remission in newly diagnosed high-risk follicular lymphoma: a pilot study of 34 cases. Leukemia 1995; 9: 576-582.
9. McQuaker IG, Haynes AP, Anderson S et al. Engraftment and molecular monitoring of CD34 positive peripheral blood stem cell transplants for follicular lymphoma: a pilot study. J Clin Oncol 1997; 15: 2288-2295.
10. Gratwohl A, Hermans J, Baldomero H. Haemopoietic precursor cell transplants in Europe - activity in 1994. Report from the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1996; 17: 137-148.
11. To LB, Roberts MM, Haylock DN et al. Comparison of haematological recovery times and supportive care requirements for autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 1992; 9: 277-284.
12. Russell NH, Pacey S. Economic evaluation of peripheral blood stem cell transplantation for lymphoma. Lancet 1992; 340: 1280.
13. Ager S, Scott MA, Mahendra P et al. Peripheral blood stem cell transplantation after high-dose therapy in patients with malignant lymphoma: a retrospective comparison with autologous bone marrow transplantation. Bone Marrow Transplant 1995; 16: 79-83.
14. Schmitz N, Linch DC, Dreger P et al. A randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone marrow transplantation in lymphoma patients. Lancet 1996; 347: 3563-3570.
15. Bender J, To LB, Schwarzberg LS. Defining a therapeutic dose of peripheral blood stem cells. J Hematother 1992; 1: 392-342.
16. Bensinger WI, Longin K, Appebaum F et al. Peripheral blood stem cells (PBSCs) collected after recombinant granulocyte colony-stimulating factor (rhG-CSF): an analysis of factors correlating with the tempo of engraftment after transplantation. Br J Haematol 1994; 87: 825-831.
17. Haas R, Mohle R, Fruhauf S et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787-3794.
18. Haynes A, Hunter A, McQuaker G et al. Engraftment characteristics of peripheral blood stem cells mobilized with cyclophosphamide and the delayed addition of G-CSF. Bone Marrow Transplant 1995; 16: 359-363.
19. + cell counts decrease haematological toxicity of autologous peripheral blood progenitor cell transplantation. Blood 1998; 91: 3148-3155.
20. Weaver CH, Hazelton B, Birch R et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961-3969.
21. Perry A, Watts M, Peniket A et al. Progenitor cell yields are frequently poor in patients with indolent lymphomas especially when mobilized within 6 months of previous therapy. Bone Marrow Transplant 1998; 21: 1201-1205.
22. Ketterer N, Salles G, Moullet I et al. Factors associated with successful mobilization of peripheral blood progenitor cells in 200 patients with lymphoid malignancies. Br J Haematol 1998; 103: 235-242.
23. McQuaker IG, Haynes AP, Stainer C et al. Stem cell mobilisation in resistant or relapsed lymphoma: superior yield of progenitor cells following a salvage regimen comprising ifosphamide, etoposide and epirubicin compared to intermediate dose cyclophosphamide. Br J Haematol 1997; 98: 228-233.
24. Cullen MH, Stuart NSA, Woodroffe C et al. Ch1VPP/PAB1OE and radiotherapy in advanced Hodgkin's disease. J Clin Oncol 1994; 12: 779-787,
25. + selection of autologous or allogeneic PBSC collections. J Hematother 1998; 7: 375-383.
26. McQuaker IG, Hunter AE, Pacey S et al. Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral blood stem cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. J Clin Oncol 1996; 15: 451-457.
27. Aurlien E, Holte H, Pharo A et al. Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide and G-CSF can effectively mobilise PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma. Bone Marrow Transplant 1998; 21: 873-878.
28. Martinez C, Mateu R, Sureda A et al. Peripheral blood stem cell mobilisation following salvage therapy (JAPVP-16) plus granulocyte colony-stimulating factor and autografting for non-Hodgkin's lymphoma. Transplant Proc 1995; 27: 2355-2356.
29. Pettengell R, Testa NG, Swindell R et al. Transplantation potential of hematopoietic cells released into the circulation during routine chemotherapy for non-Hodgkin's lymphoma. Blood 1993; 82: 2239-2248.
30. 2 + G-CSF mobilisation in pre-treated lymphoma patients. Blood 1996; 88 (Suppl. 1): 396a.
31. McQuaker IG, Haynes AP, Fletcher J et al. G-IVE salvage therapy for relapsed lymphoma results in high response rates and allows rapid progression to high-dose therapy. Br J Haematol 1998; 101 (Suppl. 1): 83a.
32. Jackson GH, Angus B, Carey PJ et al. High dose ifosfamide in combination with etoposide and epirubicin followed by autologous stem cell transplantation in the treatment of relapsed/refractory Hodgkin's disease - a report on the toxicity and efficacy (submitted).